Skip to main content

Sanofi swings to loss as dupixent drives sales higher

Sanofi SA swung to a net loss in its fourth quarter results Thursday after booking impairment charges on a number of its assets, but reported rising sales on the back of a strong performance from Dupixent--a treatment for eczema and other allergic diseases.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.